- Report
- May 2026
- 156 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 152 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 157 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 146 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 148 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 146 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 146 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 149 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 149 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 148 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 150 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- February 2026
- 142 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- March 2026
- 212 Pages
Global
From €4411EUR$4,850USD£3,779GBP
- Report
- May 2026
- 145 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 150 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 148 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 156 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 153 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 149 Pages
Global
From €3592EUR$3,950USD£3,078GBP
- Report
- May 2026
- 152 Pages
Global
From €3592EUR$3,950USD£3,078GBP

Prostate cancer is a type of cancer that affects the prostate, a small walnut-shaped gland in men that produces the seminal fluid that nourishes and transports sperm. It is the most common cancer in men in the United States, and the second most common cause of cancer death in men. Prostate cancer is typically treated with surgery, radiation therapy, hormone therapy, chemotherapy, or a combination of these treatments.
The prostate cancer market within the oncology space is a rapidly growing segment, driven by the increasing prevalence of the disease and the development of new treatments. The market is expected to benefit from the introduction of novel therapies, such as immunotherapies and targeted therapies, which are expected to improve the prognosis of patients. Additionally, the increasing focus on early diagnosis and the development of new diagnostic tools are expected to drive the market growth.
Some of the key players in the prostate cancer market include AstraZeneca, Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Pfizer Inc., and Sanofi. Show Less Read more